Ikena Oncology Inc (IKNA)
1.69
-0.02
(-1.17%)
USD |
NASDAQ |
Nov 15, 16:00
1.68
-0.01
(-0.59%)
After-Hours: 20:00
Ikena Oncology Research and Development Expense (TTM): 40.57M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 40.57M |
| June 30, 2024 | 48.40M |
| March 31, 2024 | 53.74M |
| December 31, 2023 | 59.65M |
| September 30, 2023 | 61.02M |
| June 30, 2023 | 65.21M |
| March 31, 2023 | 65.53M |
| December 31, 2022 | 64.32M |
| Date | Value |
|---|---|
| September 30, 2022 | 61.02M |
| June 30, 2022 | 55.54M |
| March 31, 2022 | 51.43M |
| December 31, 2021 | 47.11M |
| September 30, 2021 | 58.17M |
| June 30, 2021 | 52.02M |
| March 31, 2021 | 46.98M |
| December 31, 2020 | 44.85M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
40.57M
Minimum
Sep 2024
65.53M
Maximum
Mar 2023
54.72M
Average
54.64M
Median
Research and Development Expense (TTM) Benchmarks
| MediciNova Inc | 5.873M |
| NovaBay Pharmaceuticals Inc | 0.064M |
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |
| Theriva Biologics Inc | 14.61M |